Safe handling of antineoplastic drugs: Nurses' knowledge, attitudes, and practices in a Malaysian Tertiary hospital [0.03%]
马来西亚三级医院护士的抗肿瘤药物安全处理知识、态度和实践状况调查研究
Muhammad Idham Jasmiad,Nur Izzati Mansor,Amira Raudhah Abdullah et al.
Muhammad Idham Jasmiad et al.
IntroductionAntineoplastic agents (ANPDs) are mainly used in the treatment of cancer, with known health risks to nurses involved in the handling of these agents. Despite growing awareness, studies continue to reveal incomplete adherence to ...
CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners [0.03%]
CDK4/6抑制剂在浸润性小叶癌中的疗效、耐药模式和内分泌搭档疗法
Saim Mahmood Khan,Aroobah Jawwad,Maheen Kashif et al.
Saim Mahmood Khan et al.
BackgroundBreast cancer (BC) remains the most common malignancy in women, with 10-15% being invasive lobular carcinoma (ILC). ILC is typically estrogen receptor (ER) positive, slow-growing, and characterized by multicentricity, multifocalit...
Assessment of chemotherapy dosing and regimen optimization in geriatric oncology patients diagnosed with solid organ malignancies [0.03%]
老年实体瘤患者化疗剂量和方案优化的评估
Prajwal R Shankar,Harshitha Bv,Sangeetha S et al.
Prajwal R Shankar et al.
IntroductionThe rising geriatric population has led to an increase in cancer diagnoses, with treatment decisions complicated by variable functional status and co-morbidities. This study compared chemotherapy dosing strategies, evaluated eff...
Cost-effectiveness of chemotherapy versus targeted therapy in breast cancer: A retrospective analysis in tertiary care hospital [0.03%]
乳腺癌化疗与靶向治疗的 cost-effectiveness：一家三级保健医院的回顾性分析
Naresh Kunta,Sriharsha Varakala,Vaishnavi Devi et al.
Naresh Kunta et al.
BackgroundBreast cancer represents a significant economic burden globally, with treatment costs varying substantially between conventional chemotherapy and newer targeted therapies. Economic evaluation is essential for healthcare decision-m...
The impact of treatment duration on quality of life, economic burden, and work productivity among chronic myeloid leukemia survivors [0.03%]
治疗持续时间对慢性髓性白血病幸存者生活质量、经济负担和工作生产力的影响
Lingling Li,Sasa Li,Youwei Yang et al.
Lingling Li et al.
ObjectiveTo explore the impact of treatment duration on quality of life (QoL), economic burden, and work productivity among chronic myeloid leukemia (CML) survivors.MethodsA single-center cross-sectional design was adopted, and 72 CML survi...
Impact of healthcare providers' training (ISOPP-OPAB) on biosimilars use for cancer care at a university hospital in Nigeria [0.03%]
ISCOPE-OPAB培训对尼日利亚大学医院癌症护理中生物类似药使用的影响
Modupe Lydia Olarewaju,Raheem Bolanle Rahamon,Oluwabusayo Abolarin et al.
Modupe Lydia Olarewaju et al.
This study assessed the impact of a targeted training program offered by the International Society of Oncology Pharmacy Practitioners in enhancing biosimilar knowledge among healthcare professionals at the University of Ilorin Teaching Hosp...
Contamination on the external surface of hazardous drug vials wrapped in Vial Protect Pack shrink tack labels [0.03%]
Vial Protect Pack收缩标签包装的危险药物西林瓶外表面污染状况的研究
Paul Sessink,Motohiko Sano
Paul Sessink
PurposeExternal contamination of hazardous drug vials poses significant risks of environmental contamination and occupational exposure. This study evaluated the effectiveness of Vial Protect Pack shrink-tack labels (VPP I and II) in prevent...
Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database [0.03%]
基于FDA不良事件报告系统（FAERS）数据库的法布替尼（一种成纤维细胞生长因子受体抑制剂）药物警戒分析
Connor Frey
Connor Frey
BackgroundFutibatinib, a novel FGFR inhibitor, is a promising therapy for cancers with FGFR alterations. However, its safety profile remains under investigation. This study evaluates futibatinib-associated adverse events using the FDA Adver...
Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience [0.03%]
帕唑帕尼减量策略治疗复发、晚期或转移性肉瘤的单中心经验报告
Chaeyeong Jang,Kevin Chen,Samantha A Armstrong et al.
Chaeyeong Jang et al.
IntroductionPazopanib is a treatment option for patients who have advanced or metastatic soft tissue sarcoma. Although the FDA label recommends pazopanib 800 mg q24h as the initial dose, the starting dose in clinical practice can range from...